The start of diet season - January through April - looks bright for Medifast so far, says the company's CEO Michael MacDonald, as does Medifast's expansion plans into Canada. And while diet and nutrition stocks underperformed the S&P last year, MacDonald says the diet pill craze was not a factor. He also says the recent headlines over Nu Skin's operations in China, as well as Herbalife's fight with Bill Ackman are not having an impact on Medifast's business or digital marketing campaigns.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.